It was recently found that PRG4 is expressed in liver and HCC tissues and is able to enhance sorafenib and regorafenib effectiveness in slowing down the in vitro proliferation of HCC cells expressing the PRG4 receptor CD44 [53]. This evidence concerns the gene CD44 and hepatocellular carcinoma.